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A skein of silk (purple) emerging
from the anterior spinneret of a
Spiny back spider (Castercantha sp.).
The spider has been stimulated
to secrete silk from its piriform gland
spigots (orange and yellow). In the
Spiny back spider, the orientation of
the spigots is critical to the
organization of the narrow-gauge
secreted strands that are fused
together to form the final silk strand.
The scanning electron micrograph
has been colored to emphasize
morphological features.
For more details, see Thiel et al.,
Biopolymers 1994, 34:1089–1097.
(Image provided by Dennis Kunkel,
Pacific Biomedical Research Center,
University of Hawaii at Manoa,
Honolulu, Hawaii 96822, USA.)
Review
A lust for science
Peter Goodfellow
The unlikely hero of Mendel’s Dwarf,
Benedict (Ben) Lambert, will be
familiar to many readers. Many of us
have worked with scientists like Ben,
have heard them lecture and read
their work. But even if you can relate
to Ben as a character, Simon Mawer’s
revelations about the man behind
the science will probably come as
something of a shock. Ben is
obsessed with science, sex, Mendel
and Mrs Jean Miller.
Ben Lambert’s research group is
responsible for showing that FGF3 is
mutated in achondroplasia, the most
common form of dwarfism. Ben
himself is an achondroplastic dwarf
(giving news headline writers the
opportunity for such gems as: “Dwarf
biologist discovers himself”). He is
also featured in a television
documentary that seeks to show the
world, scientific and non-scientific,
through Ben’s eyes.
Peer recognition follows and he is
invited to give a keynote lecture at
the Mendel Symposium in Brno. For
Ben, this is both a spiritual and
family homecoming as he is a great-
great-great nephew of Mendel. As
you might imagine him boasting
after a few beers, Ben shares 3% of
his genes with a genius. An added
bonus in the novel is a synopsis of
the Mendel Lecture in which Ben
castigates the eugenics trends that
often stalk advances in genetics.
Ben is a scientist, Ben is a
geneticist, Ben is a dwarf but,
ultimately, Ben is a man. Some will
find Mawer’s book distasteful because
of its focus on sex. Men have a Y
chromosome which encodes the SRY
gene that induces testicular
development, and testes produce
testosterone. I recall a parents’
evening at my son’s primary school.




not mention masturbation in sex
education classes. The Chairman of
the Governors, a local priest, replied
that 99% of men masturbated and that
he had no idea what the other 1% did.
Ben Lambert is a fervid member
of the 99% club and early chapters
of Mendel’s Dwarf are reminiscent of
Portnoy’s Complaint. The later
chapters chronicle Ben’s attachment
to, and love affair with, Mrs Jean
Miller. We learn of the growing
bond between them, the
consummation of their affair and the
final Faustian agreement by which
Mrs Miller consents to one final
sexual act in return for impregnation
with an egg fertilised by Ben’s
sperm but guaranteed free of
mutation in the FGF3 gene.
Inevitably, tragedy follows.
Does it help to portray scientists
in the grip of lust? I am not sure. For
my tastes, the novel takes on too
many themes: the whole of genetics,
the sex lives of both Mendel and
Ben, the bitterness of the
phenotypically unusual, eugenics
and the attractions of Mrs Miller.
Each is worth a book in itself.
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What is it famous for? At the moment,
failing to merge with Glaxo
Wellcome. These two giants of the
British pharmaceutical industry
recently caused havoc on the stock
markets by announcing a hastily
formed merger agreement that just as
rapidly fell apart. This mother of all
mergers would have created the
world’s third largest company, with a
market value of £100 billion, and the
biggest drug company by far with 8%
of the world market, way ahead of the
nearest rivals, Merck and Novartis.
But wasn’t SmithKline merging with
AHP? Secret merger talks with AHP
(American Home Products) started
last November. But no sooner was a
deal announced in January than
SmithKline got a better offer from
Glaxo Wellcome and pulled the plug
on AHP.
So is SmithKline an attractive partner?
SmithKline has two drugs that each
make more than a billion dollars a
year: the anti-depressant Seroxat (the
main rival to Prozac) and the
antibiotic Augmentin. Other
products include an arthritis drug,
Relifex, and a successful range of
vaccines but much of its revenue in
fact comes from an enormous range
of consumer brands and over-the-
counter remedies. It was expected
that merger with Glaxo Wellcome
would have meant abandoning some
of SmithKline’s best-selling drugs to
avoid a regulatory enquiry, such as
the anti-herpes drug Famvir and the
anti-nausea drug Kytril.
What about basic research? The
company opened a state-of-the-art
research facility a year ago in
Harlow, UK at a cost of £250
million. It has invested heavily in
genetic research, especially in gene
identification technology, defining
hundreds of pharmaceutical
development targets. But that’s an
expensive business. One of the
much-touted benefits of the merger
with Glaxo Wellcome was the huge
Research and Development
organization it would have created
— with a budget of £1.9 billion,
twice that of the nearest rival.
What’s it like to work there? Since
SmithKline Beecham was created
from SmithKline Beckman (US) and
the UK’s Beecham Group in 1989, it
has been far more an American
company than anything else. Anyone
used to an academic environment
might find the prevailing smart dress
code and nine-to-five mentality
somewhat strange, but it’s rumoured
that at least the Research and
Development Division — of which
eccentric former Cambridge
Genetics Professor Peter Goodfellow
is Vice-President — still manages to
retain an unorthodox atmosphere
more condusive to research.
Why did the Glaxo Wellcome merger
collapse? The deal is thought to have
foundered because of a clash of
management egos. Certainly, both
SmithKline’s Chief Executive Jan
Leschly — a go-getting Dane and
former world-class tennis player —
and Glaxo’s Executive Chairman
Richard Sykes are powerful
personalities. The break-up is
particularly embarrassing for
SmithKline. As one city fund
manager said: “SmithKline has
already jilted the bride to run off with
the best man. Now they cannot even
get it together with the best man.”
So is it a case of ‘divided we fall’?
There is speculation that SmithKline
has made itself a target for an
aggressive takeover. The company
will certainly have its work cut out to
restore its credibility. Both Augmentin
and Seroxat face challenges to patent
protection and may soon have
generic competition. SmithKline
needs to prove it can produce major
new drugs to replace them.
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